Oncology News | pharmaphorum

News

MSD, Moderna start phase 3 trial of mRNA cancer jab

MSD & Co and Moderna have advanced a combination of an mRNA-based cancer vaccine and checkpoint inhibitor Keytruda into a phase 3 trial in skin cancer melanoma, althou

News

Humanigen facing bankruptcy as reverse merger fails

Three years ago, Humanigen was riding high with a COVID-19 therapy in late-stage testing and shares worth upwards of $20 apiece.

News

Gilead drops magrolimab for myelodysplastic syndromes

Gilead Sciences has said it will stop the development of its cancer antibody magrolimab in blood cancer myelodysplastic syndromes (MDS) after disappointing results in a ph

News

EMA panel rejects Mirati’s KRAS drug Krazati

Mirati Therapeutics’ hopes of an EU approval for its KRAS inhibitor Krazati in the EU have been thrown into disarray after the EMA’s human medicines committee rejected the

News

AbbVie nears EU nod for DLBCL drug epcoritamab

AbbVie and Genmab’s would-be blockbuster epcoritamab has been recommended for conditional approval in the EU as a treatment for diffuse large B-cell lymphoma (DLBCL), an a

News

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years a

MSD, Moderna start phase 3 trial of mRNA cancer jab

Humanigen facing bankruptcy as reverse merger fails

Gilead drops magrolimab for myelodysplastic syndromes

EMA panel rejects Mirati’s KRAS drug Krazati

AbbVie nears EU nod for DLBCL drug epcoritamab

FDA okays Daiichi Sankyo’s Vanflyta for first-line AML

CMS aims for broader GLP-1 access via federal programmes

How to meet your physicians where they are online

News

Editor's Picks